Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb randomized double-blind trial of ACYW135 meningococcal conjugate vaccine (CRM197) in adults 18–59 years
CTR20240193Phase 3Active
- Sponsor
- CanSino Biologics Inc.
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acyw135 meningococcal conjugate vaccine crm197 in meningococcal meningitis (2 arms), sponsored by CanSino Biologics Inc. Started Mar 2024; status: active.
02
Drugs
acyw135 meningococcal conjugate vaccine crm197
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on CTR20240193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240193.